Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: Health check programmes for chronic disease have been introduced in a number of countries. However, there are few trials assessing the benefits and harms of these screening programmes at the population level. In a post hoc analysis, we evaluated the effect of population-based screening for type 2 diabetes and cardiovascular risk factors on mortality rates and cardiovascular events. METHODS: This register-based, non-randomised, controlled trial included men and women aged 40-69 years without known diabetes who were registered with a general practice in Denmark (n = 1,912,392). Between 2001 and 2006, 153,107 individuals registered with 181 practices participating in the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION)-Denmark study were sent a diabetes risk score questionnaire. Individuals at moderate-to-high risk were invited to visit their GP for assessment of diabetes status and cardiovascular risk (screening group). The 1,759,285 individuals registered with all other general practices in Denmark constituted the retrospectively constructed no-screening (control) group. Outcomes were mortality rate and cardiovascular events (cardiovascular disease death, non-fatal ischaemic heart disease or stroke). The analysis was performed according to the intention-to-screen principle. RESULTS: Among the screening group, 27,177 (18%) individuals attended for assessment of diabetes status and cardiovascular risk. Of these, 1,533 were diagnosed with diabetes. During a median follow-up of 9.5 years, there were 11,826 deaths in the screening group and 141,719 in the no-screening group (HR 0.99 [95% CI 0.96, 1.02], p = 0.66). There were 17,941 cardiovascular events in the screening group and 208,476 in the no-screening group (HR 0.99 [0.96, 1.02], p = 0.49). CONCLUSIONS/INTERPRETATION: A population-based stepwise screening programme for type 2 diabetes and cardiovascular risk factors among all middle-aged adults in Denmark was not associated with a reduction in rate of mortality or cardiovascular events between 2001 and 2012.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The same researchers found that population-based stepwise screening for T2DM and CVD among all middle-aged adults was not associated with a reduction in mortality or CV events.”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [76]
The cited source says what the claim attributes to it.
In the citing paper
“Therefore, the benefits of population-based screening are limited in this context [76].”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290 · cited 4×
“%) had high CVD risk (European Heart SCORE ≥ 5 points).”
BackgroundInfluential(1967) · Project Euclid (Cornell University) · Cited by 4,720
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014 · cited 1×
“For cancers such as prostate, any effect of screening on population mortality rates is achieved largely through the effect of treatment in the lead time between detection by screening and clinical diagnosis [24].”
BackgroundProceedings of the fifth Berkeley symposium on mathematical statistics and probability.
Kojima, K.-I. (1969) · Europe PMC (PubMed Central) · Cited by 3,648
International Standard Classification of Education, ISCED 1997
UNESCO United Nations Educational, S. A. C. O. (2003) · Advances in Cross-National Comparison · doi:10.1007/978-1-4419-9186-7_10 · Cited by 2,351
The International Standard Classification of Education 2011
Schneider, S. L. (2013) · Comparative Social Research · doi:10.1108/s0195-6310(2013)0000030017 · Cited by 886
Griffin, S. J., Borch-Johnsen, K., Davies, M. J., Khunti, K., Rutten, G. E., Sandbæk, A., Sharp, S. J., Simmons, R. K., van den Donk, M., Wareham, N. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60698-3 · Cited by 462 · cited 5×
“Although earlier detection may have benefitted those diagnosed with diabetes [18], the proportion was probably too small to affect population mortality rates.”
BackgroundMethodResultInfluentialSelf-citationHerman, W. H., Ye, W., Griffin, S. J., Simmons, R. K., Davies, M. J., Khunti, K., Rutten, G. E. H. M., Sandbaek, A., Lauritzen, T., Borch-Johnsen, K., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2459 · Cited by 340
Self-citationA Danish Diabetes Risk Score for Targeted Screening
Glümer, C., Carstensen, B., Sandbæk, A., Lauritzen, T., Jørgensen, T., & Borch-Johnsen, K. (2004) · Diabetes Care · doi:10.2337/diacare.27.3.727 · Cited by 324 · cited 4×
“We used a validated risk score developed and evaluated in a Danish population to identify those at high risk of undiagnosed diabetes [15].”
BackgroundMethodInfluentialSelf-citationSiu, A. L., & on behalf of the U.S. Preventive Services Task Force* (2015) · Annals of Internal Medicine · doi:10.7326/m15-2345 · Cited by 319 · cited 2×
“As governments seek to apply the principles of prevention to chronic disease, health check programmes have been proposed or introduced in a number of countries, including the UK and the USA [1, 2].”
BackgroundInfluentialJorgensen, T., Jacobsen, R. K., Toft, U., Aadahl, M., Glumer, C., & Pisinger, C. (2014) · BMJ · doi:10.1136/bmj.g3617 · Cited by 296 · cited 2×
“INTER-99 reported no effect and the Västerbotten Intervention Programme, which combined screening with a wider public health promotion programme, reported mortality rate reductions [9, 11].”
BackgroundGeneral health checks in adults for reducing morbidity and mortality from disease
Krogsbøll, L. T., Jørgensen, K. J., Grønhøj Larsen, C., & Gøtzsche, P. C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009009.pub2 · Cited by 289
Kahn, R., Alperin, P., Eddy, D., Borch-Johnsen, K., Buse, J., Feigelman, J., Gregg, E., Holman, R. R., Kirkman, M. S., Stern, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62162-0 · Cited by 287
Self-citationSimmons, R. K., Echouffo-Tcheugui, J. B., Sharp, S. J., Sargeant, L. A., Williams, K. M., Prevost, A. T., Kinmonth, A. L., Wareham, N. J., & Griffin, S. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61422-6 · Cited by 252 · cited 2×
“However, our findings mirror those of a pragmatic, parallel-group, cluster-randomised trial in 33 general practices in eastern England (ADDITION-Cambridge) [8], in which screening for type 2 diabetes in those at high risk did not result in a reduction in all-cause or cardiovascular- or diabetesrelated mortality rates…”
BackgroundResultSelf-citationGRuttenfor the ADDITION Study Group, Lauritzen, T., Griffin, S., Borch-Johnsen, K., Wareham, N., & Wolffenbuttel, B. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801420 · Cited by 249 · cited 2×
“ADDITION-Denmark consists of two phases: a pragmatic screening programme; and a cluster-randomised trial comparing the effects of intensive multifactorial therapy with routine care among individuals with screen-detected type 2 diabetes [13, 14].”
BackgroundSelf-citationThe NHS Health Check in England: an evaluation of the first 4 years
Robson, J., Dostal, I., Sheikh, A., Eldridge, S., Madurasinghe, V., Griffiths, C., Coupland, C., & Hippisley-Cox, J. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-008840 · Cited by 184 · cited 1×
“Furthermore, there is evidence of sub-optimal treatment among individuals identified at high risk in health check programmes [27] and among those with screen-detected diabetes [18], which might have contributed to the lack of difference between groups.”
BackgroundPutting prevention first - vascular checks: risk assessment and management
Young, H. (2010) · Cited by 160
Eborall, H. C., Griffin, S. J., Prevost, A. T., Kinmonth, A.-L., French, D. P., & Sutton, S. (2007) · BMJ · doi:10.1136/bmj.39303.723449.55 · Cited by 137 · cited 1×
“However, previous research suggests that such adverse effects are limited in both the short and longer term [31, 32].”
BackgroundSelf-citationWhy cancer screening has never been shown to “save lives”—and what we can do about it
Prasad, V., Lenzer, J., & Newman, D. H. (2016) · BMJ · doi:10.1136/bmj.h6080 · Cited by 137
Christensen, J. O., Sandb�k, A., Lauritzen, T., & Borch‐Johnsen, K. (2004) · Diabetologia · doi:10.1007/s00125-004-1496-2 · Cited by 101 · cited 3×
“ADDITION-Denmark consists of two phases: a pragmatic screening programme; and a cluster-randomised trial comparing the effects of intensive multifactorial therapy with routine care among individuals with screen-detected type 2 diabetes [13, 14].”
BackgroundSelf-citationBlomstedt, Y., Norberg, M., Stenlund, H., Nyström, L., Lönnberg, G., Boman, K., Wall, S., & Weinehall, L. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009651 · Cited by 95 · cited 3×
“A more recent screening and health promotion CVD intervention undertaken in Västerbotten County, Sweden, also showed a significant long-term reduction in all-cause and CVD mortality rates when compared with the general Swedish population [11].”
BackgroundMethodEborall, H., Davies, R., Kinmonth, A. L., Griffin, S. J., & Lawton, J. (2007) · BMJ · doi:10.1136/bmj.39308.392176.be · Cited by 81 · cited 1×
“However, previous research suggests that such adverse effects are limited in both the short and longer term [31, 32].”
BackgroundSelf-citationSimmons, R. K., Griffin, S. J., Lauritzen, T., & Sandbæk, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4299-y · Cited by 69 · cited 1×
“Furthermore, in a separate paper comparing the mortality rate and cardiovascular outcomes in individuals with incident diabetes in the screened group with those from the unscreened group, we show significant benefits for those diagnosed with diabetes in the screening practices [34].”
BackgroundSelf-citationSimmons, R. K., Rahman, M., Jakes, R. W., Yuyun, M. F., Niggebrugge, A., Hennings, S., Williams, D. R. R., Wareham, N. J., & Griffin, S. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1949-8 · Cited by 64 · cited 1×
“This finding was supported by examination of the Ely cohort [22], in which individuals aged 40–65 years who were invited to diabetes screening every 5 years between 1990 and 1999 had a non-significant 21% lower all-cause mortality rate than individuals who were not invited to screening; however, this finding was not r…”
ResultSelf-citationWho attends a UK diabetes screening programme? Findings from the ADDITION‐Cambridge study
Sargeant, L. A., Simmons, R. K., Barling, R. S., Butler, R., Williams, K. M., Prevost, A. T., Kinmonth, A. L., Wareham, N. J., & Griffin, S. J. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03056.x · Cited by 61 · cited 2×
“Furthermore, screening attendees are frequently those at lowest risk [23].”
BackgroundSelf-citationKuo, H. S., Chang, H., Chou, P., Teng, L. Y., & Chen, T. H. (1999) · International Journal of Epidemiology · doi:10.1093/ije/28.2.233 · Cited by 59
A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis
Schuetz, C. A., Alperin, P., Guda, S., van Herick, A., Cariou, B., Eddy, D. M., Gumprecht, J., Nicolucci, A., Schwarz, P. E. H., Wareham, N. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066454 · Cited by 47
Self-citationSpijkerman, A. M. W., Griffin, S. J., Dekker, J., Nijpels, G., & Wareham, N. J. (2002) · Journal of Medical Screening · doi:10.1136/jms.9.4.187 · Cited by 39 · cited 1×
“6% were found with IFG/IGT and 48% with elevated cardiovascular risk (SCORE > 5 points), providing a larger at-risk group with the potential to benefit from interventions to prevent both diabetes and CVD [25, 26].”
BackgroundSelf-citationGeneral practitioners’ adherence to guidelines on management of dyslipidaemia: ADDITION-Denmark
Graversen, L., Christensen, B., Borch‐Johnsen, K., Lauritzen, T., & Sandbæk, A. (2009) · Scandinavian Journal of Primary Health Care · doi:10.3109/02813430903335216 · Cited by 21 · cited 1×
“0mmol/l and LDL-cholesterol <3 mmol/l within 1 year of starting treatment [29].”
BackgroundSelf-citationChang, H.-J., Kuo, H., Tung, T., Chou, P., & Chen, T. H.-H. (2000) · Preventive Medicine · doi:10.1006/pmed.2000.0728 · Cited by 15
Simmons, R. K., Carlsen, A. H., Griffin, S. J., Charles, M., Christiansen, J. S., Borch‐Johnsen, K., Sandbæk, A., & Lauritzen, T. (2014) · Diabetic Medicine · doi:10.1111/dme.12574 · Cited by 13 · cited 1×
“Among those with screen-detected diabetes, there was wide variation between general practices in prescription of lipid-lowering treatment [30].”
BackgroundSelf-citationRasmussen, S. S., Johansen, N. B., Witte, D. R., Borch‐Johnsen, K., Sandbæk, A., Lauritzen, T., & Jørgensen, M. E. (2016) · Diabetologia · doi:10.1007/s00125-016-3887-6 · Cited by 13 · cited 1×
“6% were found with IFG/IGT and 48% with elevated cardiovascular risk (SCORE > 5 points), providing a larger at-risk group with the potential to benefit from interventions to prevent both diabetes and CVD [25, 26].”
BackgroundSelf-citationGraversen, L., Christensen, B., Borch‐Johnsen, K., Lauritzen, T., & Sandbæk, A. (2011) · Scandinavian Journal of Primary Health Care · doi:10.3109/02813432.2011.629148 · Cited by 7 · cited 1×
“Indeed, follow-up of ADDITION-Denmark participants who did not have diabetes but had high CVD risk and dyslipidaemia showed that only 20% were started on lipid-lowering treatment following screening [28].”
BackgroundSelf-citationAlberti (1998) · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s · cited 6×
“While small numbers of individuals were diagnosed with diabetes following screening in Denmark (1%), 1.6% were found with IFG/IGT and 48% with elevated cardiovascular risk (SCORE > 5 points), providing a larger at-risk group with the potential to benefit from interventions to prevent both diabetes and CVD [25, 26].”
Influential
Cited by
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312
General health checks in adults for reducing morbidity and mortality from disease
Krogsbøll, L. T., Jørgensen, K. J., & Gøtzsche, P. C. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009009.pub3 · Cited by 202
INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"
Dedov, I. I., Shestakova, M. V., Mel'nichenko, G. A., Mazurina, N. V., Andreeva, E. N., Bondarenko, I. Z., Руслановна, Г. З., Dzgoeva, F. K., Елисеев, М. С., Ershova, E. V., et al. (2021) · Obesity and metabolism · doi:10.14341/omet12714 · Cited by 206
Screening for type 2 diabetes mellitus
Peer, N., Balakrishna, Y., & Durão, S. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005266.pub2 · Cited by 122
“Another study evaluated the impact of training general practitioners for intensive management of patients with screen-detected diabetes (Simmons 2017).”
BackgroundSimmons, R. K., Griffin, S. J., Lauritzen, T., & Sandbæk, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4299-y · Cited by 69
Self-citation
Metadata
- Authors
- Simmons, R. K., Griffin, S. J., Witte, D. R., Borch-Johnsen, K., Lauritzen, T., & Sandbæk, A.
- Affiliations
- Steno Diabetes Centers (DK)
- Aarhus University (DK)
- Corresponding author
- Simmons, Rebecca K.
- Venue
- Diabetologia
- Published
- 2017-08-23
- Volume
- 60
- Issue
- 11
- Pages
- 2183-2191
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC6086322
- OpenAlex
- W2617354269
- Cited by
- 51
- References
- 35
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 2 · 2022: 6 · 2021: 6 · 2020: 7 · 2019: 8 · 2018: 7 · 2017: 5
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diabetologia (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- Pfizer
- GlaxoSmithKline
- Strategiske Forskningsråd
- Aarhus Universitet
- Sundhed og Sygdom, Det Frie Forskningsråd
- Steno Diabetes Center Copenhagen (SDCC 3.A Complications)
- National Institute for Health and Care Research (NF-SI-0515-10119)
- Aarhus Universitets Forskningsfond
- Novo Nordisk
- Servier
- Medical Research Council (MC_UU_12015/4)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- type 2 diabetes screening, cardiovascular risk factors, mass screening, mortality, cardiovascular events, ischemic heart disease, stroke, middle-aged adults, primary care, screening benefits and harms, Denmark, cardiovascular mortality, intention-to-treat analysis, post hoc analysis
- MeSH terms
- Adult, Aged, Blood Glucose, Cardiovascular Diseases, Denmark, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Male, Mass Screening, Middle Aged, Risk Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
